Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × Alopecia × Clear all

Phase

Phase NA 2 Phase 2 1

Status

Completed 2 Withdrawn 1 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 101 Carcinoma, Non-Small-Cell Lung 92 Multiple Myeloma 60 Prostatic Neoplasms 59 Colorectal Neoplasms 57 Neoplasm Metastasis 55 Neoplasms 50 Lung Neoplasms 39 Leukemia, Myeloid, Acute 38 Recurrence 37 Carcinoma, Hepatocellular 36 Lymphoma 34 Melanoma 30 Leukemia, Lymphocytic, Chronic, B-Cell 30 Pancreatic Neoplasms 27 Lymphoma, Large B-Cell, Diffuse 24 Head and Neck Neoplasms 23 Squamous Cell Carcinoma of Head and Neck 22 Rectal Neoplasms 22 Leukemia 22 Glioblastoma 22 Ovarian Neoplasms 21 Myelodysplastic Syndromes 19 Hematologic Neoplasms 19 Brain Neoplasms 19 Colonic Neoplasms 18 Carcinoma, Renal Cell 18 Uterine Cervical Neoplasms 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Burkitt Lymphoma 17

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00746980 2016-06-14

Efalizumab in the Treatment of Alopecia, Phase II

Northwestern University

Phase 2 Withdrawn

Alopecia, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡